National and Kapodistrian University of Athens
Η κλινική σημασία των ανοσοϋποδοχέων PD σε ασθενείς με διάχυτα λεμφώματα από μεγάλα B κύτταρα: συσχέτιση με κλινικά και παθολογοανατομικά ευρήματα των ασθενών
Abstract
dc:descriptionDiffuse Large B-Cell Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and belongs to the aggressive subtypes. At cellular and molecular level its clinical course and the prognosis of patients with this malignancy appear to depend to a large extent on the escape of lymphoma cells from the immune system and specifically from T lymphocytes. The immunosuppressive receptor of lymphocytes, programmed cell death-1 (PD-1), plays an inhibitory role in the proliferation and activation of T lymphocytes and, therefore, in the immune surveillance and destruction of neoplastic cells through its binding to 2 ligands, PD-L1 (CD274 or B7-H1) and PD-L2 (CD273 or B7-DC). PD-1 signaling physiologically attenuates T cell activation and protects adjacent tissues from the spread of inflammation, providing a balance between an effective immune response and immune-induced tissue damage, but in the case of malignant cells PD-1 plays a negative role as it contributes to the immune escape of neoplastic cells.PD-L1 has been detected in biopsies mainly of patients with Primary Mediastinal Large B-cell Lymphoma (PMLBCL) but also in patients with DLBCL of the non-germinal center histological subtype (non-GCB). Moreover, in patients with DLBCL, the PD-1 receptor has been detected in both lymphoma cells and tumor infiltrating lymphocytes (TILs).The present study aimed to investigate possible pathogenetic pathways and molecular mechanisms of refractoriness to chemotherapy of DLBCL cells, specifically among DLBCL, not otherwise specified (NOS) patients, who constitute at least 25-30% of all DLBCL cases. Our study showed that PD-L1 expression is not an independent prognostic factor for the overall survival in patients with DLBCL, NOS, it appearshowever that immunohistochemical detection of immunoreceptors and their ligands in DLBCL, NOS is still far from being objective or trustworthy. Another finding of our study is that PD-L1 positive DLBCL, NOS is primarily associated with the non-GCB histological subtype, as described in other studies as well. In summary, our study suggests that PD-L1 expression in patients with DLBCL, NOS could lead to more aggressive biological behaviors and inhibition of the PD-1 / PD-L1 pathway with monoclonal antibodies may be of value in these patients. However, the patients who will benefit the most from targeted immunomodulatory therapies (as well as those who are most likely to experience severe side effects), the most appropriate time and route of administration, and their duration are still unknown and should be clearly identified, as well as predictors of response to treatment.Of great interest is the possible combination of cytotoxic therapies with immunoreceptor inhibitors. However, the biggest challenge in the near future will be to find the optimal possible combination of therapies that target the various mechanisms by which lymphoma cells evade immune system mechanisms. This discovery will pave the way for completely personalized treatments for patients with recurrent or refractory lymphoma, or even under 1st line treatment.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karakatsanis, Stamatis
- Καρακατσάνης, Σταμάτης
Subjects
dc:subject × 21- Διάχυτο λέμφωμα από μεγάλα Β κύτταρα
- Υψηλής κακοήθειας Non-Hodgkin λεμφώματα
- Ανοσοδιαφυγή
- Programmed cell death
- Λεμφοκύτταρα που ανευρίσκονται μεταξύ των νεοπλασματικών κυττάρων
- Χημειοανθεκτικότητα
- Στοχευμένες ανοσοτροποποιητικές θεραπείες
- Υποτροπιάζον / ανθεκτικό στην θεραπεία λέμφωμα
- Diffuse Large B-Cell Lymphoma, DLBCL
- Aggressive Non-Hodgkin lymphomas
- Immunoevasion
- Tumor Infiltrating Lymphocytes, TILs
- Chemoresistance
- Targeted immunomodulatory therapies
- Relpased / refractory lymphoma
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Αιματολογία
- Clinical Medicine
- Medical and Health Sciences
- Hematology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49830